Lords Mark Q2 FY27: consol PAT margin nearly halves to 4.6% as revenue rises 22% QoQ
margins compressing · miss vs street
₹375.73 Cr
₹17.26 Cr
4.55%
+20.3pp YoY
₹0.4
Lord's Mark Industries (formerly Kratos Energy & Infrastructure) reported consolidated revenue from operations of ₹375.73 Cr for Q2 FY27, up 22.1% QoQ from ₹307.68 Cr in Q1 FY27, but consolidated PAT fell 48.0% QoQ to ₹17.26 Cr from ₹33.18 Cr, taking net profit margin down to 4.59% from 10.61% and operating (EBITDA) margin to roughly 8.1% from about 16.0%. Standalone PAT of ₹15.83 Cr (EPS ₹0.37; consolidated EPS ₹0.40) tracked the same compression, confirming the squeeze sits at the parent level rather than in a subsidiary. A YoY comparison against the September-2025 quarter (revenue ₹12.64 Cr, loss ₹2.11 Cr) is not meaningful since that quarter predates the reverse amalgamation of Kratos Energy with Lords Mark India that created the current, much larger entity.
Q2 FY-2027 vs prior quarters
The margin bridge: cost of materials (purchase of stock-in-trade, the dominant line in this trading-heavy model) rose to about 83.5% of total income this quarter from roughly 75.3% in Q1, the main driver of the EBITDA compression. Finance costs rose 23.9% QoQ to ₹7.73 Cr as long-term borrowings jumped 53.8% half-on-half to ₹224.24 Cr (from ₹145.84 Cr at FY26-end), consistent with the board's October 19 proposal to raise up to ₹100 Cr via a promoter loan and with the ongoing Silvassa plant expansion and AI-dialysis-machine capex the company describes in its MD&A.
What the summary numbers don't show
No exceptional/extraordinary items this quarter in either statement (unlike FY26 full year's ₹4.18 Cr item)
FY27 revenue ₹1550 Cr (20% growth YoY). FY28 revenue >₹2000 Cr with PAT margin 10-11%. Medtech products expected Q4 FY27/Q1 FY28 launch. Dialysis 50 centers by FY27-end.
There is no formal sell-side consensus on this name (0-1 analysts per our pre-result tracking, rated Hold, though retail sentiment ran 85% Buy); our pre-result preview had flagged ~₹300-350 Cr revenue, 20-21% EBITDA margin and 12-13% PAT margin as the on-plan bar. The print beat the revenue range (₹375.7 Cr) but missed both margin targets by a wide margin. Management's own MD&A (Annexure 2) describes a 'massive jump in sales and profitability' in the medical-device division, 26 additional manufacturing licenses, and dialysis-machine trials underway in Bangalore — none of which is reflected in the consolidated P&L this quarter, where overall profitability fell sequentially; either the device division is still too small to move the group number or its gains were offset elsewhere. Management's FY27 guidance of ₹1,550 Cr revenue (given at the Q1 concall) is 44% met at the halfway mark (₹683.4 Cr H1 revenue), requiring roughly ₹866.6 Cr across H2 to hit the target — achievable at the current QoQ growth pace, but the FY28 goal of 10-11% PAT margin looks further away given this quarter's 4.6% print and the rising cost ratio. No formal guidance update was issued in this filing.
W1
Cost-of-materials ratio (83.5% of total income this quarter, up from 75.3% in Q1) needs to revert for PAT margin to rebuild toward the FY28 10-11% guidance from today's 4.6%
W2
H2 FY27 revenue run-rate needed (~₹866.6 Cr across two quarters) to hit the ₹1,550 Cr FY27 target after H1's ₹683.4 Cr (44% of target)
W3
Commercial launch of sickle-cell screening (flagged for January 2027) and AI-dialysis-machine export shipments (flagged from end-December) — management's own near-term catalysts in this filing's MD&A
Filing figures are in ₹ Lakh (converted ÷100 to Cr); no exceptional/extraordinary items this quarter in either statement (unlike FY26 full-year's ₹4.18 Cr item); year-ago quarter (Sep-2025) predates the Kratos Energy–Lords Mark India amalgamation (NCLT order), so YoY is not like-for-like — QoQ vs Q1 FY27 is the meaningful comparison.
Healthcare-Led Growth: Can Q2 Sustain Q1's Profit Turnaround?
Lords Mark has pivoted to profitability and targets ₹1,550 Cr for FY27. With regulatory tailwinds (MHRA, FDA approvals), Silvassa expansion ahead of schedule, and heavy medical-device capex underway, Q2 will signal whether the diversified conglomerate can scale throughput or faces execution headwinds.
The Setup: Q1's Surprise Profitability & What It Signals
Lords Mark Industries swung to consolidated net profit of ₹33.18 crore in Q1 FY27 (quarter ended June 30, 2026), a stark turnaround from a near-breakeven quarter in the prior year. Standalone revenue landed at ₹280 crore, consolidated ₹307 crore. This marks the inflection moment for a recently listed (July 2026), diversified conglomerate pivoting from legacy commodity/energy into healthcare and medical devices. The Street's consensus sits at Hold with minimal coverage, but community sentiment leans bullish (85%+ buy votes). The real question: was Q1 an outlier or the beginning of a margin-accretive trajectory?
~₹300–350 Cr
On-plan trajectory toward ₹1,550 Cr FY27 guidance; Q1 was ₹307 Cr consolidated. Sequential growth would signal healthcare capex traction.
~20–21%
FY27 guided ~20.8%; Q1 swung to profitability; watch if operating leverage holds under growth capex.
~12–13%
FY27 guided ~12.8%; Q1 delivered ₹33 Cr on ₹307 Cr revenue (~10.7%); expansion into IVD/healthcare should help.
₹300–350 Cr over 2–3 years
Heavy investment into Silvassa facility (completed ahead of schedule) and IVD manufacturing; promoter reinvesting share-sale proceeds.
A strong Q2 print would show: (1) revenue holding or growing sequentially (₹330 Cr+), (2) EBITDA margins sustaining ~20%+, (3) PAT growing to ₹35+ Cr, and (4) progress on working capital (receivables were flagged post-Q1). A weak print would signal: (1) sequential revenue decline (below ₹300 Cr), (2) margin compression below 18%, (3) PAT falling below ₹30 Cr, or (4) capex headwinds outpacing healthcare revenue ramp.
On Track? Guidance Burn-Down & Capex Reality
Lords Mark guided ₹1,550 Cr for FY27 (~20% y-o-y growth), implying Q2–Q4 needs ~₹1,243 Cr over 9 months (~₹410 Cr/qtr average). Q1 delivered only ₹307 Cr; if Q2–Q4 each land ₹410 Cr+, the guidance is easily on-plan. But the mix is critical: the company is ramping IVD and medical-device revenue while managing legacy energy/LED operations (being demerged into Lords Shakti Power). Promoter sold ~4.5% of shares in Sept–Oct 2026 and is reinvesting proceeds (₹100+ Cr) into the medical-device unit, signaling conviction but also capital intensity. Silvassa manufacturing expansion is done ahead of schedule (targeted Dec 2026, completed in Sept), so production capacity is no longer the constraint—execution and market uptake are.
Since Last Quarter: Regulatory Green Lights & Capex Push
Regulatory approvals are flowing: MHRA (UK) registered the IVD portfolio (haematological and clinical-chemistry analysers) in early Oct. FDA clearances for medical devices followed. AI-powered haemodialysis system cleared by MHRA (Sept). AI breast-cancer screening tech entered final clinical trials (Sept, multi-country). These are not revenue-accretive yet but signal de-risking of the healthcare roadmap. Capex and M&A: Silvassa facility Phase I expansion completed ahead of schedule (Sept, capacity boost for surgical instruments). Radio Electric (Radiotone brand) acquired for ₹4.5 Cr (Oct), adding lighting/electrical products. Promoter announced ₹100 Cr loan from personal funds (Oct 23 board meet), underscoring commitment but also capital needs. Shareholding: Achieved 25% minimum public shareholding (Sept 30) post-IPO, hitting SEBI compliance. Promoter reduced stake from ~80% to ~79% through sales and reinvestment.
1 · Revenue Trajectory & Mix
Does Q2 revenue land ₹330 Cr+ and show growth momentum, or does it plateau near Q1? Crucially, what % is now from IVD/healthcare (the high-margin pivot) vs legacy operations? Any breakdown on international sales or export orders (FDA/MHRA approvals should unlock new markets)?
2 · Margin Resilience Under Capex
EBITDA margins hold at 20%+ despite heavy investment, or do they slip to 18–19%? PAT trajectory — is Q2 profit higher than Q1's ₹33 Cr? Watch for one-time items, amortization spikes from M&A (Radiotone), or forex headwinds on exports.
3 · Capex Deployment & FY28 Visibility
Management guidance on when IVD/healthcare revenue scales materially (is ₹2,000 Cr by FY28 still on plan?). Progress on clinical trials, market uptake of AI diagnostics, and integration of Radiotone. Any refinement to capex pace or margin trajectory post-Silvassa completion?
Lords Mark Industries has moved the needle from breakeven to ₹33 Cr profitability in Q1 and is riding regulatory tailwinds (MHRA, FDA, MHRA again for AI diagnostics) into healthcare. The ₹1,550 Cr FY27 guidance is on-plan mathematically, but Q2 will test whether the profit surge was genuine margin expansion or a mix benefit. Heavy capex into Silvassa, IVD manufacturing, and medical-device R&D adds execution risk, but promoter reinvestment (₹100+ Cr into the unit) and early regulatory success suggest seriousness. Watch revenue growth, margin hold, and capex ROI — the Street is waiting for confirmation before upgrading from Hold.